AngioDynamics Kicks Off New Clinical Trial for PE Treatment
AngioDynamics, Inc. (NASDAQ: ANGO) has just announced the start of the RECOVER-AV trial, marking a pivotal moment for the company as it expands into the European market with its AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System. This trial aims to evaluate the safety and effectiveness of the device for treating acute, intermediate-risk pulmonary embolism (PE) after the successful completion of patient enrollment in the U.S.-based APEX-AV study in late 2023.
Key Details about the RECOVER-AV Study
The RECOVER-AV study will take place in up to 20 hospitals across Europe, aiming to deliver detailed insights into how well the AlphaVac F1885 System performs. The study primarily seeks to measure specific outcomes, such as the reduction in the right ventricular to left ventricular (RV/LV) ratio within 48 hours after treatment, while also keeping track of any Major Adverse Events (MAEs) for seven days post-procedure. Participants will be closely monitored over a full year, with follow-up assessments occurring at 30 days, six months, and one year.
Leadership and Commitment to Research
The trial is co-led by Dr. Erik Klok and Dr. Andrew Sharp, backed by an experienced international advisory board. This venture into international research represents AngioDynamics' commitment to enhancing treatment options for pulmonary embolism, a serious health issue in the EU, where it is estimated to cause around 435,000 incidents annually across key countries.
Overview of the AlphaVac System
Recently, the AlphaVac F1885 System earned its CE Mark approval, allowing for its non-surgical application to remove thromboemboli from pulmonary arteries. AngioDynamics remains dedicated to evidence-based treatments and continues to focus on improving care quality for patients around the world.
AngioDynamics' Recent Financial Results
In the last few quarters, AngioDynamics reported a modest revenue that exceeded expectations, reaching a pro forma revenue of $71.1 million. This growth seems primarily driven by their Med Tech division, which achieved fourth-quarter sales of $29.3 million. The company also announced a $15 million share buyback program, reflecting favorable outcomes from its earlier established three-year strategy.
Revenue Forecast for Fiscal Year 2025
Looking ahead to the upcoming fiscal year, AngioDynamics has set a promising revenue forecast, estimating it will fall between $282 million and $288 million. Although the company has faced some challenges, resulting in a revenue decline of 10.28% over the past year, analysts still see strong market potential for the company. Canaccord Genuity has maintained a Buy rating, despite adjusting the price target.
Strategic Restructuring and Future Opportunities
AngioDynamics has recently made significant strategic changes, including selling off its Dialysis and BioSentry divisions to focus more on its core capabilities. This progress indicates a commitment to refining its product portfolio while pursuing opportunities within its Med Tech segment.
Innovations Ahead
With a focus on upcoming products like AlphaVac, NanoKnife, and Auryon, AngioDynamics is on track for ongoing growth. These innovations reflect the company's forward momentum and determination to offer practical solutions for complex medical conditions.
Frequently Asked Questions
What is the RECOVER-AV trial?
The RECOVER-AV trial is a clinical study focused on evaluating the AlphaVac F1885 System for treating pulmonary embolism in patients across Europe.
Who is in charge of the RECOVER-AV trial?
The trial is co-led by Dr. Erik Klok and Dr. Andrew Sharp, with support from an international advisory board.
What are the main objectives of the trial?
The trial's primary objectives are to assess reductions in the RV/LV ratio and to monitor for Major Adverse Events after the procedure.
What does CE Mark approval mean for the AlphaVac System?
CE Mark approval signifies that the AlphaVac System meets European standards for safety and efficacy, allowing its use in clinical environments.
What is AngioDynamics' revenue outlook for 2025?
AngioDynamics anticipates revenue between $282 million and $288 million for the fiscal year 2025, indicating a potential for growth.
